Comparative Pharmacology
Head-to-head clinical analysis: FENOPROFEN CALCIUM versus NAPRELAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENOPROFEN CALCIUM versus NAPRELAN.
FENOPROFEN CALCIUM vs NAPRELAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates pain, inflammation, and fever.
Oral: 300-600 mg every 6-8 hours as needed; maximum 3200 mg/day.
750 mg to 1000 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is 2–3 hours; may be prolonged in elderly and patients with hepatic impairment.
Terminal elimination half-life: 10-20 hours; context: allows twice-daily or once-daily dosing for chronic pain or inflammation.
Primarily renal; approximately 90% of a dose is excreted in urine as glucuronide conjugates and unchanged drug; <2% excreted in feces.
Renal: 50-60% as metabolites and conjugates; biliary/fecal: ~5%; remainder uncharacterized.
Category C
Category C
NSAID
NSAID